The last few years have seen major developments in the management of bone and mineral disorders associated with chronic kidney disease (CKD). Acknowledgment of the fact that these bone and mineral abnormalities in CKD patients have a major impact on morbidity and mortality drove nephrologists' attention to the importance of controlling these alterations. In addition, new compounds have been developed for the control of hyperphosphatemia and for the treatment of secondary hyperparathyroidism, raising many questions toward the use of non-calcium-containing phosphate binders.
Until recently, the only phosphate binders available were aluminum or calcium-based compounds. These compounds were efficacious but were also associated with significant side effects. The use of aluminum-containing phosphate binders is associated with bone disease as well as hematologic and central nervous system toxicity, whereas the use of calcium-containing phosphate binders is associated with increased risk of hypercalcemia and cardiovascular calcification. [1] [2] [3] [4] It is now known that serum calcium levels are not accurate in predicting the calcium balance and burden. The excessive amount of calcium ingested from diet and calcium-containing binders has been associated with cardiovascular calcifications, even in the presence of normal calcium serum levels. [1] [2] [3] [4] The non-calcium, non-metal-containing, and non-absorbed phosphate binder, sevelamer hydrochloride, has provided an effective way to bind phosphorus in the gut without the risks of hypercalcemia, soft tissue or vascular calcifications, or heavy metal accumulation.
EFFECTS ON VASCULAR CALCIFICATION
In recent years, it has become clear that the presence of elevated serum phosphorus levels in CKD stage 5 patients is positively associated with increased mortality. 5, 6 Hyperphosphatemia and elevated calcium-phosphorus product (Ca X P) are associated with cardiovascular calcification. 1, 2 Cardiovascular calcification is an independent predictor of mortality. Several authors have now reported a strong positive association between the presence and extent of vascular calcification and both cardiovascular and all-cause mortality.
3,7, 8 Raggi et al. 9 reported that previous myocardial infarction, angina, and known coronary artery disease were all more common in CKD stage 5 patients with extensive calcification. Most stage 5 CKD patients present with hyperphosphatemia. The clinical outcomes of this mineral abnormality include secondary hyperparathyroidism with consequent renal bone disease, extra-osseous calcification, and increased mortality.
Therapeutic strategies to control phosphorus levels include dietary restrictions, dialysis, and the use of phosphate-binding agents. Reduction of phosphate intake in the diet is often difficult and is also limited by the associated protein restriction, as all proteins contain phosphate. Phosphate is also difficult to remove by dialysis. Increased dialysis time or frequency may be effective, but it is often difficult to implement because of logistic problems and poor patient acceptance.
Sevelamer hydrochloride has been widely studied and shown to be effective in reducing phosphorus levels and Ca X P without causing hypercalcemia and soft tissue calcification in stage 5 CKD population on hemodialysis, with the added benefit of cholesterol reduction (total and low-density lipoprotein cholesterol). This compound is well tolerated with few side effects, the more frequently reported ones being diarrhea, constipation, dyspepsia, nausea, and vomiting.
Chertow et al. 4 reported the results of a randomized parallel design clinical trial comparing sevelamer with calcium-based phosphorus binders in 200 hemodialysis patients. Sevelamer and calcium-based compounds provided similar control of serum phosphorus and Ca X P. Adherence to the prescribed dose of binder in the sevelamer and calcium-containing binder groups was similar: 86 vs 80%, respectively. The group treated with sevelamer received an average binder dose of 6.5±2.9 g per day and the group treated with calcium-based binders, 4.3 ± 1.9 g per day (4.6 and 3.9 g per day of calcium acetate or calcium carbonate, respectively). The calcium-based group had more frequent episodes of hypercalcemia when compared with the sevelamer group: 43 and 17%, respectively. Suppression of intact parathyroid hormone secretion below the 150-300 pg/ml range was more common at the end of the study in the calcium-based binders group, 57 vs 30%, despite the protocol-specified reduction or cessation of vitamin D for intact parathyroid hormone below 150 pg/ml. Twelve percent of patients in the calcium group required rescue therapy with aluminum-containing binders for a calcium-phosphorus product above 72 mg 2 /100ml 2 , compared with 4% of patients in the sevelamer group. Total and low-density lipoprotein cholesterol decreased significantly in the sevelamer-treated group compared with a non-change in the calcium binders group. It is relevant that, the electron beam computed tomography (EBCT) performed at the beginning of the study detected a prevalence of coronary artery calcification of 83% and aortic calcification of 80% of the study patients. There was significant progression of the coronary artery and aortic calcification EBCT score, at weeks 26 and 52, in the calciumcontaining binders-treated group, despite the use of an average dose of calcium-containing binders of only 4.3±1.9 g per day, which corresponds to values of elemental calcium under the Kidney Disease Outcomes Quality Initiative recommendations. There was no significant progression in the sevelamer-treated group.
The high prevalence of vascular calcification seen in the dialysis population in the Chertow study 4 has been confirmed by other reports and is of major concern because of the positive association between the presence and severity of calcification and mortality in this population. There is also some evidence that most of the patients develop vascular calcifications while on hemodialysis treatment. In fact, a report from Spiegel et al. 10 revealed that only 34% of patients with advanced CKD starting dialysis had coronary artery calcifications scores that placed them above the 90th percentile for age and sex. In the same patient population initiating dialysis, 109 patients underwent baseline and at least one additional measurement of coronary artery calcification. 11 At baseline, 37% of the patients who underwent treatment with sevelamer and 31% of the patients who underwent treatment with calcium-based binders had no evidence of calcification. The authors report that no patients with a zero coronary calcium score progressed to a coronary artery calcium score 430, using EBCT, in an 18-month period of time. Patients already having a coronary artery calcium score 430 at baseline progressed during the time of the study in both arms. The patients treated with calciumbased binders showed a more rapid and severe progression when compared with those receiving sevelamer. It can be noted that, during this study, all the patients were maintained on dialysis with a calcium dialysate concentration of 2.5 mEq/l. The authors conclude that patients new to dialysis, with no evidence of coronary calcification, showed little evidence of disease development over a period of 18 months independent of the phosphate binder used. Patients with even little evidence of coronary calcification progress with both binders; however, the group treated with calcium-based binders have a much more severe progression when compared with the patients treated with sevelamer. 11 Without any doubt, this study confirms the importance of the Kidney Disease Outcomes Quality Initiative clinical practice guidelines for bone metabolism and disease in CKD, recommending that calcium-based binders should be avoided in patients with evidence of severe calcification. 12 'Kidney Disease: Improving Global Outcomes' has recommended a new classification for CKD mineral and bone disorder that includes for the first time the evaluation of vascular calcifications. 13 In hemodialysis patients, vascular calcifications may be evaluated by different techniques: EBCT, 14 multislice computed tomography (MSCT), 15 ultrasonography, 7 and plain X-ray. 3, 8, 16 EBCT and MSCT allow a quantitative measurement and are considered the gold standard for evaluating vascular calcification, but are very expensive. The utilization of plain X-ray for screening 13 We have developed a vascular calcification score evaluated in plain X-ray of hands and pelvis (Figure 1 ), which was a predictor of cardiovascular death and cardiovascular morbidity in dialysis patients (Figure 2) . 8 This simple vascular calcification score has been also correlated with valvular calcifications 17 and with arterial stiffness. 18 Plain X-ray and ultrasonography are semiquantitative, less expensive, and useful for screening the presence of vascular calcifications. They can be used to identify patients at higher risk of a cardiovascular event. EBCT and MSCT are useful for evaluating the progression of vascular calcification and the effect of different treatments on progression of vascular calcification. These two techniques do not differentiate intimal from medial calcification, and the explanation for the very high scores evaluated in dialysis patients is the presence of both types of calcification.
EFFECTS ON BONE
In a randomized prospective, open label study, 119 hemodialysis patients were evaluated with bone biopsies performed at the beginning and after a 1-year treatment period, to compare the effects of sevelamer hydrochloride and calcium carbonate on bone. 19 Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). The serum phosphorus levels were similarly controlled in both groups, although the serum calcium level was consistently lower and intact parathyroid hormone higher in patients treated with sevelamer. Compared with baseline values, there were no changes in mineralization lag time or measures of bone turnover after 1 year of treatment with both sevelamer and calcium carbonate. Bone formation rate per bone surface increased significantly from baseline only in the sevelamer-treated patients. In addition, of those with abnormal microarchitecture at baseline (that is, trabecular separation), 7 of 10 in the sevelamer group normalized after 1 year compared with 0 of 3 in the calcium group. In summary, this study showed that sevelamer treatment resulted in no statistically significant changes in bone turnover or mineralization compared with calcium carbonate, but bone formation rate increased and trabecular architecture improved only with sevelamer.
In a group of 42 hemodialysis patients submitted to bone biopsies, 20 we have verified that low bone volume was associated with vascular calcifications evaluated by MSCT or by plain X-ray and with higher pulse wave velocity. Adynamic bone disease was present in 50% of patients. There were no cases of osteomalacia and no aluminum deposits in bone.
London et al. 21 showed the existence of an association between vascular calcifications and low bone turnover. In this study, 58 hemodialysis patients were evaluated; 23 patients had been submitted to parathyroidectomy and 33 patients had aluminum deposits in bone. Vascular calcifications were evaluated by ultrasonography. More calcifications were associated with lower osteoblast surface and with other markers of low bone turnover, with lower parathyroid hormone levels and with higher calcium dose. Asci et al. 22 showed, in a group of 224 patients, that vascular calcifications evaluated by MSCT were associated with lower activation frequency evaluated in bone biopsies. A recent study was performed to assess the impact of bone activity on the relationships between the dosage of calciumcontaining binders and aortic stiffness or abdominal aorta calcification score. 23 A significant interaction was found between the dosage of calcium-containing phosphate binders and bone activity such that the calcium load had a significantly higher impact on aortic calcifications and stiffening in the presence of adynamic bone disease.
The data presented suggest that sevelamer treatment has a beneficial effect on bone, with an increase in the bone formation rate and an improvement in the trabecular architecture. There is an association between vascular calcifications and low bone volume and with low bone turnover in dialysis patients. Finally, in dialysis patients with adynamic bone, calcium load has a greater influence on aortic calcifications and stiffening. Patients whose bone is not able to retain calcium or phosphorus have higher vascular calcification scores. One added risk factor for the development of vascular calcifications in the setting of low bone turnover is the administration of calcium-containing phosphate binders.
A CLOSE LOOK INTO THE SURVIVAL DATA
The promise of a survival benefit with the use of sevelamer hydrochloride has been evaluated in two randomized prospective, controlled studies with interesting results that generate some controversy and certainly have not completely solved the issue.
The first was the 'Dialysis Clinical Outcomes Revisited (DCOR)' study. 24 This 3-year trial involving more than 2100 patients compared the difference in mortality and morbidity outcomes for patients receiving sevelamer hydrochloride and those receiving calcium-containing phosphate binders. This was the largest outcomes study ever conducted in the hemodialysis population. This study showed that the patients treated with sevelamer hydrochloride experienced a reduction of 7% in the risk of death from all causes when compared with the patients treated with calcium-based phosphate binders, which was statistically not significant (P ¼ 0.3). The patients aged 65 years or more (a predefined analysis) were 23% less likely to die when treated with sevelamer hydrochloride, as compared with treatment with calciumbased binders. In addition, patients treated with sevelamer hydrochloride for more than 2 years had a 34% reduction of the mortality risk for all causes compared with those treated with the calcium-containing binders.
The second study was the 'Renagel in New to Dialysis Patients.' 25 This was a randomized controlled, prospective, open label study with 127 patients incident to dialysis, assigned to 18 months treatment with sevelamer hydrochloride or calcium-containing phosphate binders, to assess coronary artery calcification progression. Mortality was a predetermined secondary end point. 25 Twenty-three deaths in the calcium-containing phosphate binders group and 11 deaths in the sevelamer hydrochloride-assigned patients occurred during the median 44 months of follow-up time after randomization, a significantly lower mortality for patients treated with sevelamer hydrochloride. The survival benefit observed with sevelamer hydrochloride treatment persisted after full multivariate adjustment.
It is very important to analyze the reasons for the differences observed in the outcomes of these two trials. The DCOR trial evaluated prevalent patients probably with a more important burden of calcification, whereas 'Renagel in New to Dialysis Patients' trial was performed in patients new to dialysis. It is probably very difficult to reverse already existing vascular calcifications. The DCOR trial has been criticized for the short follow-up time of less than 2 years. The median follow-up was shorter in the DCOR trial compared with the 'Renagel in New to Dialysis Patients' trial, 19 vs 44 months, respectively. The short follow-up time in the DCOR trial did not allow the differences in mortality to appear. In fact, for the patients followed for more than 2 years, the difference in mortality became significant. In the DCOR trial, the number of previewed cardiovascular events necessary to demonstrate a difference between the two treatment groups was not reached. The annual mortality rate in the DCOR trial was inferior to the annual mortality rate reported in United States Renal Data System. 26 The results of these two studies strongly suggest that the use of sevelamer as a phosphate binder decreases mortality in incident and in elderly hemodialysis patients and reinforces the importance of earlier initiation of treatment with sevelamer hydrochloride in hemodialysis patients.
A final comment is on the systematic review of the clinical efficacy and safety of sevelamer hydrochloride in dialysis patients published by Tonelli et al. 27 In the mortality analysis, the authors included five studies (Table 1) , with only one of them having mortality as the primary end point. 25 The other three studies included (Table 1) in the mortality analysis involved a small number of patients, had a short follow-up, and mortality was not an end point. These studies 4, 28, 29 were not powered in terms of follow-up time, number of patients, and end points to evaluate mortality. In our view, it is impossible to withdraw any mortality information in studies with 42 patients and a 5-month follow-up, or a crossover study with 20 patients and a total follow-up of 18 weeks. The Chertow study's 4 primary end point was vascular calcification; mortality was not even an end point and received 24% weight in the analysis. Regarding the 'Renagel in New to Dialysis Patients' study, with a long follow-up for the secondary end point mortality and evidence of survival benefit in the sevelamer-treated group, the weight attributed was only 4.26%.
In our opinion, the available data on mortality benefit with sevelamer hydrochloride treatment from two randomized prospective controlled trials constitute a very positive Kidney International (2008) 74 (Suppl 111), S38-S43 S41 JM Frazão and T Adragão: Sevelamer treatment, calcification, and survival r e v i e w fact that is certainly innovative in the nephrology field. We are not aware of any other pharmacological intervention in dialysis patients with such ground in terms of hard outcome data.
In a recent editorial, 30 the authors state that 'to cultivate a balanced approach to understanding results generated by meta-analysis of data from small trials it is important to accept the limitations implicit in this method.' Meta-analysis only generates hypotheses and certainly should be carefully interpreted. One should always keep in mind that welldesigned, randomized controlled trials are the strong bases for evidence-based medicine.
There is mounting evidence from basic science, 31 observational studies, 32 and randomized trials with surrogate end points such as cardiovascular calcification 4, 11 and mortality 25 that calcium can be toxic for dialysis patients. With this level of information, the nephrology community should be asking what level of scientific evidence is needed to convince us to discontinue, or at least to be extremely cautious with the use of calcium-containing phosphate binders, a potentially harmful therapy.
DISCLOSURE
João M Frazão has received consulting and lecture fees from Amgen and Genzyme. Teresa Adragão has declared no financial interests. 29 
20
Crossover study 18 weeks Biochemical parameters Suki et al. 
